Quince Therapeutics, Inc. (NASDAQ:QNCX) Receives $8.00 Average Price Target from Analysts

Shares of Quince Therapeutics, Inc. (NASDAQ:QNCXGet Free Report) have received an average rating of “Buy” from the seven ratings firms that are presently covering the firm, MarketBeat reports. Five research analysts have rated the stock with a buy rating and two have assigned a strong buy rating to the company. The average 1 year price target among analysts that have issued a report on the stock in the last year is $8.00.

Several equities research analysts recently weighed in on the stock. Brookline Capital Management initiated coverage on shares of Quince Therapeutics in a research note on Wednesday, December 18th. They set a “buy” rating and a $9.00 target price on the stock. D. Boral Capital cut their price objective on Quince Therapeutics from $12.00 to $4.00 and set a “buy” rating on the stock in a research report on Tuesday, March 25th. Finally, Oppenheimer assumed coverage on Quince Therapeutics in a report on Monday, March 24th. They issued an “outperform” rating and a $10.00 target price for the company.

Get Our Latest Report on Quince Therapeutics

Quince Therapeutics Trading Up 2.0 %

Shares of NASDAQ QNCX opened at $1.02 on Friday. The company has a current ratio of 9.53, a quick ratio of 9.53 and a debt-to-equity ratio of 0.33. The stock has a market capitalization of $44.88 million, a PE ratio of -0.82 and a beta of 0.74. Quince Therapeutics has a twelve month low of $0.51 and a twelve month high of $2.45. The stock has a fifty day simple moving average of $1.35 and a 200-day simple moving average of $1.49.

Quince Therapeutics (NASDAQ:QNCXGet Free Report) last released its earnings results on Monday, March 24th. The company reported ($0.28) earnings per share for the quarter, missing the consensus estimate of ($0.19) by ($0.09). The business had revenue of $0.17 million during the quarter. On average, equities analysts forecast that Quince Therapeutics will post -1.21 earnings per share for the current year.

Institutional Investors Weigh In On Quince Therapeutics

A number of hedge funds and other institutional investors have recently modified their holdings of QNCX. Intellectus Partners LLC acquired a new position in shares of Quince Therapeutics during the first quarter worth $71,000. Two Sigma Investments LP acquired a new position in shares of Quince Therapeutics during the 4th quarter worth about $57,000. Shay Capital LLC boosted its position in shares of Quince Therapeutics by 60.8% during the 4th quarter. Shay Capital LLC now owns 276,799 shares of the company’s stock worth $518,000 after acquiring an additional 104,616 shares in the last quarter. Northern Trust Corp increased its holdings in shares of Quince Therapeutics by 48.5% in the 4th quarter. Northern Trust Corp now owns 50,524 shares of the company’s stock valued at $94,000 after acquiring an additional 16,501 shares during the last quarter. Finally, Geode Capital Management LLC raised its position in shares of Quince Therapeutics by 10.9% during the 4th quarter. Geode Capital Management LLC now owns 375,932 shares of the company’s stock worth $703,000 after acquiring an additional 36,807 shares in the last quarter. 30.75% of the stock is currently owned by institutional investors and hedge funds.

About Quince Therapeutics

(Get Free Report

Quince Therapeutics, Inc, a biopharmaceutical company, focuses on acquiring, developing, and commercializing therapeutics for patients with debilitating and rare diseases. The company's lead asset candidature comprises EryDex for the treatment of rare pediatric neurodegenerative disease, including A-T, an inherited autosomal recessive neurodegenerative and immunodeficiency disorder caused by mutations in ATM gene.

Recommended Stories

Analyst Recommendations for Quince Therapeutics (NASDAQ:QNCX)

Receive News & Ratings for Quince Therapeutics Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Quince Therapeutics and related companies with MarketBeat.com's FREE daily email newsletter.